FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
14/03/2025
Voltar para busca
Dado oficial do USPTO
VISCOFAN FIBERCOLL-FLEX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
VISCOFAN FIBERCOLL-FLEX
ST13
US500000079353016Classe
1, 2, 5
Pedido
79353016
Registro
7497685
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
15/03/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 2, 5
Data de depósito
28/07/2022
Data de registro
10/09/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/09/2024
Última transação
15/03/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
88
Localização do titular
ES
Examinador
TWOHIG,SHANNON MARIE
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
VISCOFAN, S.A.
Representantes
Douglas A. Miro Amster, Rothstein & Ebenstein LLP
Classificação técnica
Classes Nice
Classe 1Classe 2Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Biological materials or preparations for 3D printersbioinksbioprinting kits comprised of collagenbiological printed tissues other than for medical or veterinary purposes; hydrogels for cell culture not for medical or veterinary purposes; hydrogels for cell growth not for medical or veterinary purposes; cell culture media other than for medical or veterinary use; nutritional agents for processing living cells other than for medical usecell culture media within a reservoir for growth factors; culture media for microbiology for laboratory use; reagents for scientific and medical research; synthetic peptides not for pharmaceutical purposespeptide substrates used in analyzing and detecting certain toxins for laboratory or research use; synthetic peptide derivatives not for pharmaceutical purposespeptide substrates used in analyzing and detecting certain toxins for laboratory or research use; cells other than for medicalveterinary or pharmaceutical use; cells or tissues in hydrogels other than for medicalveterinary or pharmaceutical use; biologically compatible polymersspecifically hydrogels used to produce polymer networks used in the manufacture of engineered living tissues for medicalscientific and non-scientific purposestissue implantsorganoidstissue models; cell culture media for use in the biotechnological industry for laboratory use; cell culture media for use in non-medical research laboratories; biological preparations for use in cell cultureother than for medical and veterinary purposes; engineered living tissues and tissue arrayshuman and animal organsconnective tissueepithelial tissuemuscular tissue and nervous tissuetissue arraysfor use in scientific and medical research; biologically compatible materialsspecificallyhydrogels used to create polymeric networks used in the manufacture of living tissues for laboratory use; proteins in the form of raw materials for scientific and medical research
Classe 2
Inks of biological origin for printers; inks of biological origin for 3D printers
Classe 5
Hydrogels for medicalveterinary and pharmaceutical purposes for cellular biology applications; hydrogels for cell growthcell growth and transplantationassays based on cellscancer cell researchregenerative medicinestem cell growth and drug delivery for medical use; hydrogels for cell culture for medicalveterinary and pharmaceutical purposes; hydrogels for cell growth for medicalveterinary and pharmaceutical purposes; cell culture media for medical use; nutritional agents for processing living cellscell culture media growth factors contained within a reservoir; synthetic peptides for the treatment of degenerated hard and soft tissues; synthetic peptide derivativesfor the treatment of degenerated hard and soft tissues; cells for medicalveterinary and pharmaceutical use; cells or tissues in hydrogels for medicalveterinary or pharmaceutical use; pharmaceutical preparations for use in 3D bio-printing of tissues and organs; pharmaceutical preparations with other materials and ingredients for use in 3D bio-printing of tissues and organs; regenerative tissue being pharmaceutical preparations for hard and soft tissue regeneration; cells for medical use; allogeneic human tissue; living cells for medical use; implants containing living tissue; implantable living tissue materials for use in guided tissue regeneration; skin grafts; surgical implants formed by living tissue; surgical implants of living tissues derived from stem cells; transdermal patches for the creation of skin for prostheses and skin grafts; living tissue for transplants; engineered biological tissues and organshuman and animal cardiovascularpulmonarydigestivehepatobiliaryurologicalrenalendocrineepithelialmuscularnervous tissues and organsfor medical purposes; biological molecules being implants comprising living tissue to assist in tissue engineeringhard and soft tissue regeneration; hemostatic gel matrix preparations for wound treatment; natural biomaterials for the growth of bonesblood and tissues for medical purposes; pharmaceutical products for the regeneration of tissuesfor the repair of tissuesfor the treatment of tissueswhether human or animal3D implants for hard and soft tissue regeneration combining bioinks and biological materials; pharmaceutical preparations for the treatment of diseases of bonescartilagesblood vesselsnerve cell degenerationtendon and ligament degenerationretinal degenerationkidney degeneration; soft tissue degenerationsfor diseases with abnormal cell growthformulated bioinks for hard and soft tissue regeneration combining bioinks and biological materials with a pharmaceutical effect; natural biomaterial for bone filling; natural biomaterial for cartilage filling; biological tissue cultures for medical use; biological tissue cultures for medical purposes; biological tissue grafts; bone and skin biological tissues impregnated with oxygen lines for tissue constructs applicable for increasing the cell survival in tissue intended for subsequent implants; gene therapy productsgenetically modified tissues for the transplant thereof; implantable stents composed primarily of living tissue to maintain the structure of the tissue; natural biomaterial for bone and tissue growth for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
20/02/2025
FIMP
FINAL DISPOSITION PROCESSED
19/02/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/12/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/09/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
10/09/2024
GPNX
NOTIFICATION PROCESSED BY IB
01/07/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/06/2024
PUBO
PUBLISHED FOR OPPOSITION
25/06/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/06/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/06/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/06/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/05/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/05/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/05/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/04/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
20/03/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
20/03/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/03/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
29/11/2023
GNFR
FINAL REFUSAL E-MAILED
29/11/2023
CNFR
FINAL REFUSAL WRITTEN
29/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/10/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/10/2023
RFNT
REFUSAL PROCESSED BY IB
17/05/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
22/04/2023
RFRR
REFUSAL PROCESSED BY MPU
22/04/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/03/2023
CNRT
NON-FINAL ACTION WRITTEN
28/02/2023
DOCK
ASSIGNED TO EXAMINER
23/02/2023
MAFR
APPLICATION FILING RECEIPT MAILED
25/10/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/10/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
20/10/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VISCOFAN FIBERCOLL-FLEX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.